Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 10:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 307 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Heart Diseases in Pregnancy Clear all
Terminated Phase 4 Interventional Results available

Curosurf and Survanta Treatment(CAST)of RDS in Very Premature Infants

NCT00767039
View directory record Official record
Conditions
Prematurity, Respiratory Distress Syndrome, Patent Ductus Arteriosus
Interventions
Survanta (beractant), Curosurf (poractant)
Drug
Lead sponsor
Alan Fujii
Other
Eligibility
Up to 8 Hours
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 3, 2011 · Synced Oct 13, 2026, 10:58 PM EDT
Completed Not applicable Interventional Results available

Aminophylline to Prevent Acute Kidney Injury in Children After Cardiac Surgery

NCT01245595
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Aminophylline, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
1 Day to 18 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 13, 2026, 10:58 PM EDT
Terminated Phase 2 Interventional

Oral Tonapofylline (BG9928) in Patients With Heart Failure and Renal Insufficiency

NCT00745316
View directory record Official record
Conditions
Renal Insufficiency, Heart Failure
Interventions
Tonapofylline, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
30
States / cities
Huntsville, Alabama • Mobile, Alabama • Scottsdale, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Oct 13, 2026, 10:58 PM EDT
Completed Phase 2 Interventional Results available

The Impact of Ketamine on Postoperative Cognitive Dysfunction, Delirium, and Renal Dysfunction

NCT02554253
View directory record Official record
Conditions
Cognitive Disorders, Delirium, Acute Kidney Injury
Interventions
Ketamine, Propofol
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
75 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Oct 13, 2026, 10:58 PM EDT
Terminated No phase listed Observational

Study to Identify Markers of Insulin Resistance During Growth Hormone Treatment for Short Stature

NCT00121875
View directory record Official record
Conditions
Turner Syndrome, Idiopathic Short Stature
Interventions
somatropin (rDNA)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 14 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 29, 2009 · Synced Oct 13, 2026, 10:58 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Do Elevated BNP Levels Predict Hemodynamically Significant PDAs

NCT01497054
View directory record Official record
Conditions
Patent Ductus Arteriosus
Interventions
Not listed
Lead sponsor
Albany Medical College
Other
Eligibility
1 Hour to 24 Hours
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jul 4, 2013 · Synced Oct 13, 2026, 10:58 PM EDT
Completed Phase 1 Interventional

VEG111485: A QTc Study of Pazopanib

NCT00861029
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Pazopanib, Placebo for pazopanib, Moxifloxacin, Placebo for moxifloxacin
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
Duarte, California • Santa Monica, California • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 13, 2026, 10:58 PM EDT
Completed Phase 3 Interventional Results available

Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome

NCT02251431
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease, Left Ventricular Diastolic Dysfunction
Interventions
BYDUREON, Placebo
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 13, 2026, 10:58 PM EDT
Active, not recruiting No phase listed Observational

The Heart Outcomes in Pregnancy Expectations (H.O.P.E) Registry

NCT04828070
View directory record Official record
Conditions
Pregnancy Related, Cardiac Disease
Interventions
Observation
Other
Lead sponsor
Saint Luke's Health System
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 13, 2026, 10:58 PM EDT
Terminated Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE)

NCT06602453
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
GDC-8264, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
40 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Stanford, California • Tampa, Florida • Lutherville, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 13, 2026, 10:58 PM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Finger Plethysmography to Predict Fluid Responsiveness in Healthy Pregnancy and Severe Preeclampsia

NCT07430254
View directory record Official record
Conditions
Pre-Eclampsia, Severe, Pregnancy
Interventions
Noninvasive finger plethysmographic cardiac output monitoring, Standard transthoracic echocardiographic assessment
Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 13, 2026, 10:58 PM EDT
Completed Phase 2 Interventional Results available

Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug

NCT04534114
View directory record Official record
Conditions
End Stage Renal Disease Requiring Hemodialysis
Interventions
Fesomersen sodium (BAY2976217), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
9
States / cities
Clovis, California • Victorville, California • Fort Lauderdale, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 13, 2026, 10:58 PM EDT
Terminated Phase 2 Interventional Results available

Randomized Controlled Trial to Evaluate the Safety and Efficacy of Acetaminophen in Preterm Infants Used in Combination With Ibuprofen for Closure of the Ductus Arteriosus

NCT03701074
View directory record Official record
Conditions
Patent Ductus Arteriosus, Preterm Infant, Bronchopulmonary Dysplasia
Interventions
Ibuprofen and acetaminophen, Ibuprofen and placebo
Drug
Lead sponsor
University of South Alabama
Other
Eligibility
5 Days to 21 Days
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 13, 2026, 10:58 PM EDT
Completed Phase 3 Interventional Results available

Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)

NCT03888066
View directory record Official record
Conditions
Hyperkalemia
Interventions
Patiromer, Placebos
Drug
Lead sponsor
Vifor Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
133
States / cities
Alexander City, Alabama • Huntsville, Alabama • Phoenix, Arizona + 110 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2023 · Synced Oct 13, 2026, 10:58 PM EDT
Active, not recruiting Not applicable Interventional

Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates

NCT03674307
View directory record Official record
Conditions
Cardiovascular Diseases, End Stage Renal Disease, Kidney Transplantation, Dialysis Related Complication
Interventions
No screening, Regular Screening
Other
Lead sponsor
University of British Columbia
Other
Eligibility
18 Years and older
Enrollment
3,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Tucson, Arizona • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 13, 2026, 10:58 PM EDT
Completed Phase 2 Interventional

Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder

NCT06206512
View directory record Official record
Conditions
Heart Failure, Overactive Bladder, Incontinence
Interventions
Extended release torsemide, Immediate release torsemide, Extended release torsemide placebo, Immediate release torsemide placebo
Drug
Lead sponsor
Sarfez Pharmaceuticals, Inc.
Industry
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 13, 2026, 10:58 PM EDT
Withdrawn No phase listed Observational

Hematologic Ratios in Postoperative Acute Kidney Injury

NCT03658148
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Cardiac Surgery with Cardiopulmonary Bypass
Procedure
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
0 Days to 31 Days
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Oct 13, 2026, 10:58 PM EDT
Completed Phase 1Phase 2 Interventional

Safety Study of Cenderitide in Chronic Stable Heart Failure With Moderate Renal Impairment

NCT02603614
View directory record Official record
Conditions
Heart Failure, Renal Insufficiency
Interventions
Cenderitide, Placebo
Drug
Lead sponsor
Capricor Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Oct 13, 2026, 10:58 PM EDT
Completed No phase listed Observational

Sequential Cystatin C Levels and Renal Impairment in Acute Heart Failure

NCT00561483
View directory record Official record
Conditions
Acute Heart Failure, Renal Failure
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 13, 2026, 10:58 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)

NCT04752293
View directory record Official record
Conditions
Hypertension, Left Ventricular Hypertrophy, Left Ventricular Dysfunction, Left Atrial Dilatation, Left Ventricular Diastolic Dysfunction, Kidney Diseases, Kidney Injury, Kidney Dysfunction, Sodium Urine High, Blood Pressure Disorders, Uric Acid Retention, Angiotensin Hypertension, Autonomic Dysfunction, Autonomic Imbalance, Pediatric Kidney Disease, Pediatric Obesity, Proteinuria, Albuminuria
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
7 Years to 18 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 13, 2026, 10:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

This Study Will Investigate the Effect of Single Oral Doses of Retosiban on Cardiac Repolarization, With Moxifloxacin as a Positive Control in Healthy Volunteers.

NCT01702376
View directory record Official record
Conditions
Obstetric Labour, Premature
Interventions
Retosiban 100 mg, Retosiban 800 mg, Placebo, Moxifloxacin 400 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 13, 2026, 10:58 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

NCT03989115
View directory record Official record
Conditions
Solid Tumor
Interventions
RMC-4630, Cobimetinib, Drug: Osimertinib
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
21
States / cities
Scottsdale, Arizona • Duarte, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 13, 2026, 10:58 PM EDT
Terminated Not applicable Interventional

CPAP vs.Unsynchronized NIPPV at Equal Mean Airway Pressure

NCT03670732
View directory record Official record
Conditions
Prematurity, Respiratory Distress Syndrome, Apnea of Prematurity
Interventions
continuous positive airway pressure, nasal intermittent positive pressure ventilation
Other
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
Up to 6 Months
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 13, 2026, 10:58 PM EDT
Completed No phase listed Observational

"Treatment Use of ECMO In Pregnancy or Peripartum Patient."

NCT04144660
View directory record Official record
Conditions
Cardiogenic Shock, Peripartum Cardiomyopathy, Complication, Pregnancy
Interventions
Extracorporeal Membrane Oxygenation
Device
Lead sponsor
Sarah Thordsen
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 13, 2026, 10:58 PM EDT